[New aspects in prevention and therapy of diabetic nephropathy]

The reduction of micro- and macrovascular end points in patients with diabetes mellitus type 2 is achieved by control of traditional risk factors such as hyperglycemia, hyperlipidemia, obesity and hypertension. However, most of the glucose lowering medication available is excreted by the kidney. Thus, in patients with diabetes-associated chronic kidney disease, the glucose lowering therapy has to account for renal function to avoid hypoglycemic episodes and other side effects such as lactic acidosis due to metformin.